Single-cell analysis

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Retrieved on: 
星期一, 五月 6, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, BMG, Cell biology, Single-cell analysis, Luminescence, Apoptosis, Microplate, Organoid, Partnership, Sampling, University, Early access, CBEC, BioRxiv, Student, Drug discovery

Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.

Key Points: 
  • Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.
  • In addition, Sampling Human has partnered with BMG LABTECH to release an application note pairing their kits with BMG LABTECH microplate readers.
  • Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference.
  • “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev.

Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer

Retrieved on: 
星期二, 四月 30, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Lead, Single-cell analysis, Bio-Rad Laboratories, Microfluidics, Marketing, NanoString Technologies, Molecular biology, Genetics, Retirement, IPO, Sphere, Senior, Bachelor of Science, Sphere Fluidics, Acquisition, Synthetic biology, Illumina, Inc., La Trobe University

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.

Key Points: 
  • In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.
  • Throughout his career, Dale has focused on supporting early-stage and VC-backed pioneering tools companies and steering them towards global market success.
  • Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, before becoming CEO in 2010.
  • Dale Levitzke, incoming CEO, Sphere Fluidics, added: “Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development.

Sphere Fluidics Appoints Edward Rayner as Non-Executive Director

Retrieved on: 
星期三, 四月 17, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Single-cell analysis, University of Oxford, Management, Ed, Master of Science, Sphere Fluidics, AMP Capital, Drug development, Growth

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a Non-Executive Director.

Key Points: 
  • Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a Non-Executive Director.
  • He has an MA in Chemistry and MSc in Management from Oxford University, and is a Chartered Financial Analyst.
  • Dr. Frank F. Craig, CEO, Sphere Fluidics, commented: “We’re very pleased that Ed has joined the Sphere Fluidics Board.
  • His acumen will help us map out our growth plans, competitive positioning and a strong exit.”
    Ed Rayner, Non-Executive Board Director, Sphere Fluidics, added: “I’m excited to join the Sphere Fluidics Board to support the Company as it accelerates its commercial roll out.

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

Retrieved on: 
星期三, 三月 27, 2024
Constellation, Single-cell analysis, Lung cancer, EGFR, Health, Biotechnology, Rachel Haurwitz, New Jersey Medical School, Foundation Medicine, Cornell University, University, Knowledge, American Cancer Society, Research, Esperion Therapeutics, Cancer, A.I, Medicine, Summit Health, Esperies, Therapy, Drug development, Partner, MorphoSys, JPMorgan Chase, Thomas Jefferson University Hospital

to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.

Key Points: 
  • to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
  • Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025.
  • Bolstering our Board with such seasoned leaders will be a key factor to success.”
    Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries.
  • Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences.

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Retrieved on: 
星期四, 三月 14, 2024
ARK, Single-cell analysis, Genomics, Gene, Cell, Disease, Drug discovery, General partnership, Patient, Tissue, Khosla Ventures, AI, Biology, Therapy, Osteoporosis, Machine learning, Ark Invest, NVIDIA, Relation, Pharmaceutical industry

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Key Points: 
  • Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
    London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
  • David Roblin, CEO of Relation Therapeutics, said: "This financing is a significant milestone for Relation Therapeutics and underscores the confidence our investors have in our innovative approach to drug discovery and development.
  • Our technology platform, uniquely integrated with deep R&D expertise, places us in an outstanding position to transform drug discovery.
  • “We see Relation as a leader in the emerging techbio economy,” said Jason Pontin, General Partner at DCVC, who sits on Relation’s board.

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
星期二, 四月 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期四, 三月 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)

Retrieved on: 
星期四, 三月 21, 2024
Single-cell analysis, Stanford University, Doctor of Philosophy, Fluency, Cell, Messenger, CRISPR

WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 /PRNewswire/ -- Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).
  • The PIPseq platform provides an instrument and microfluidics-free approach for single cell analysis, eliminating barriers to accessibility and program costs that limit routine application of high-throughout single cell analysis.
  • These early access kits allow for universal capture of CRISPR guide-RNA in addition to 3' mRNA capture from single-cell suspensions, enabling complex perturbation screening at unprecedented scale and cost.
  • For more information or consideration for early access evaluation of PIPseq-CRISPR reagents, please contact us [email protected] .

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
星期四, 三月 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .

Factorial Biotechnologies Unveils Mosaic™: Enabling Single-Cell Analysis Across All Omic Applications

Retrieved on: 
星期一, 二月 5, 2024
SAN, Life, Workflow, RNA, Research, DNA, Innovation system, Biomarker, Single-cell analysis, Disease, NGS, Medicine, Health, Library

Mosaic transcends limitations by offering the broadest content single-cell platform, enabling single-cell resolution across a wide range of NGS applications.

Key Points: 
  • Mosaic transcends limitations by offering the broadest content single-cell platform, enabling single-cell resolution across a wide range of NGS applications.
  • Factorial opens early access program for researchers interested in single-cell DNA sequencing and multi-omic applications.
  • Recognizing the immense demand in this disruptive technology, Factorial is extending an early access program for researchers interested in single-cell DNA sequencing and multi-omic applications.
  • "Mosaic represents a pivotal moment in single-cell analysis," states John Wells, founder and CEO of Factorial Biotechnologies.